Aldeyra Therapeutics (ALDX) AI Stock Analysis

• Market Cap: $85.46M
• Dividend Yield: N/A
• Average Volume (3M): 1.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.33
• Revenue Growth: N/A
• EPS Growth: 4.23%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 60,182,780
• 10 Day Avg. Volume: 1,876,110
• 30 Day Avg. Volume: 1,121,844
• PEG Ratio: 0.23
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -637.86K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 427.88M
• Enterprise Value/Ebitda: -50.22
• 1Y Price Target: $5.50
• Price Target Upside: 287.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.18
• Revenue Forecast (FY): $69.98M

• Rating: 41 Neutral
• Price Target: $1.50 ▲(5.63% Upside)
• Action: Upgraded Date: 03/19/26
• Date: Action: Upgraded 03/19/26

The score is primarily pressured by weak financial performance (pre-revenue, recurring losses, and elevated cash burn in the latest period) and a decisively bearish technical trend (price far below key moving averages with negative MACD). The second FDA Complete Response Letter adds significant product/regulatory uncertainty, while valuation signals are limited by negative earnings and no dividend yield support.

Positive Factors

Differentiated scientific approach (RASP modulation)

Aldeyra's focus on RASP modulation represents a distinct mechanistic approach to inflammatory ocular disease. That scientific differentiation supports durable R&D optionality, potential for targeted biomarker strategies, and makes the company a more attractive partner or acquirer even if individual trials are mixed.

Focused ophthalmology pipeline

A concentrated pipeline in ophthalmology concentrates R&D and commercial planning in a defined therapeutic niche. This specialization improves expertise, regulatory familiarity, and potential commercial clarity for payors and physicians, aiding longer-term execution if efficacy issues are resolved for lead programs.

Substantial cash runway and moderate leverage

Reported cash and securities expected to fund operations into 2028, combined with historically low-to-moderate debt, give the company time to pursue regulatory dialogue, additional analyses, or targeted studies without immediate insolvency risk. That runway supports strategic flexibility over the medium term.

Negative Factors

Regulatory setback — second FDA Complete Response Letter

A second FDA CRL on efficacy is a structural adverse event that undermines the core approval pathway for reproxalap, increasing the probability of prolonged review, additional requirements, or program failure. For a company anchored by this lead asset, the setback materially raises long-term commercial uncertainty.

Pre-revenue with persistent losses and weak cash generation

The company remains pre-revenue with recurring net losses and sustained negative operating and free cash flow. This structural lack of internal cash generation forces reliance on external financing, increases dilution risk, and limits strategic optionality if development costs or timelines expand.

Risk of additional costly trials and financing strain

The FDA's recommendation to analyze failures and the prospect that additional trials may be required creates substantial execution and funding risk. New large trials would materially increase cash burn and timeline, heightening dilution risk and pressuring a small company with limited staff and resources.

Aldeyra Therapeutics Business Overview & Revenue Model

Company Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

How the Company Makes Money

null

Aldeyra Therapeutics Financial Statement Overview

Summary

Pre-revenue profile with persistent net losses and consistently negative operating/free cash flow. Cash burn improved in 2023–2024 versus 2022 but worsened sharply in the most recent annual period, raising financing/dilution risk. Balance sheet leverage is relatively moderate for a biotech, but deeply negative ROE and rising leverage in the latest period are notable risks.

Income Statement

The company reports no revenue across the annual periods provided, which keeps profitability structurally negative. Losses have been persistent (net income negative each year), and while 2023–2024 losses narrowed versus 2022, the most recent annual period shows a sharp deterioration in operating results. Overall, the income profile reflects an early-stage biotech model with heavy R&D spending and limited near-term earnings visibility.

Balance Sheet

Leverage appears moderate with debt-to-equity generally low-to-moderate (roughly 0.08–0.35 across the periods), which is a relative strength for a pre-revenue biotech. However, returns on equity are deeply negative each year, indicating ongoing equity value erosion from sustained losses. The latest annual period also shows higher leverage than prior years, increasing financial risk if losses persist.

Cash Flow

Cash generation is weak with operating and free cash flow consistently negative, indicating ongoing cash burn to fund operations. Cash burn improved in 2023–2024 versus 2022, but the latest annual period shows a very large step-up in outflows, raising near-term funding risk. Free cash flow generally tracks net losses closely, suggesting limited non-cash offsets and continued reliance on external capital.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-251.99K	0.00	0.00	0.00	0.00
EBITDA	-31.69M	-53.68M	-35.21M	-60.07M	-55.77M
Net Income	-33.85M	-55.85M	-37.54M	-62.02M	-57.78M
Balance Sheet
Total Assets	72.06T	104.61M	148.33M	181.29M	233.14M
Cash, Cash Equivalents and Short-Term Investments	70.04T	101.15M	142.82M	174.30M	229.79M
Total Debt	15.53T	15.30M	15.66M	16.08M	15.86M
Total Liabilities	27.81T	33.60M	28.53M	30.28M	27.40M
Stockholders Equity	44.25T	71.00M	119.80M	151.01M	205.74M
Cash Flow
Free Cash Flow	-33.35T	-43.21M	-30.33M	-56.65M	-42.56M
Operating Cash Flow	-33.35T	-43.21M	-30.33M	-56.64M	-42.56M
Investing Cash Flow	47.74T	-44.92M	30.00M	-29.95M	-7.81K
Financing Cash Flow	1.12T	-171.42K	-1.27M	1.22M	194.50M

Aldeyra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALDX, the sentiment is Negative. The current price of 1.42 is below the 20-day moving average (MA) of 4.65, below the 50-day MA of 4.84, and below the 200-day MA of 4.87, indicating a bearish trend. The MACD of -0.64 indicates Positive momentum. The RSI at 20.36 is Positive, neither overbought nor oversold. The STOCH value of 8.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALDX.

Aldeyra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NMRA	52 Neutral	$441.12M	-1.30	-113.81%	―	―	20.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMER	50 Neutral	$776.36M	-2.20	57.33%	―	―	12.32%
CADL	47 Neutral	$369.16M	-7.84	-51.44%	―	―	68.53%
GALT	46 Neutral	$181.51M	-8.32	32.59%	―	―	18.82%
FHTX	45 Neutral	$286.46M	-4.58	105.48%	―	-3.91%	37.89%
ALDX	41 Neutral	$85.46M	-9.19	>-0.01%	―	―	4.23%

Aldeyra Therapeutics Corporate Events

FDA Issues Second Complete Response Letter for Reproxalap

On March 17, 2026, Aldeyra Therapeutics announced that the U.S. Food and Drug Administration issued a Complete Response Letter rejecting the New Drug Application for reproxalap in dry eye disease, citing a lack of substantial evidence of efficacy, inconsistent study results, and concerns over the reliability and meaningfulness of positive findings, although no safety or manufacturing issues were raised. The decision followed a prior Complete Response Letter in April 2025 and subsequent additional trials and resubmissions, and while Aldeyra plans to seek a Type A meeting with the FDA to clarify a path forward without conducting new trials, the setback raises significant uncertainty over eventual approval and commercialization of reproxalap, even as the company reports $70 million in cash and securities expected to fund operations into 2028.

Aldeyra previously received a Complete Response Letter in April 2025 for reproxalap over inadequate evidence of efficacy and then ran an additional dry eye chamber trial that met its primary endpoint, resubmitting the NDA in June 2025 before the FDA again determined in March 2026 that the totality of evidence did not support effectiveness in treating signs and symptoms of dry eye disease. The FDA recommended Aldeyra analyze reasons for trial failures and identify patient populations or conditions where reproxalap might work, and the company has warned that any future requirement for additional studies or trials could increase costs, delay any potential approval, and have a material adverse effect on its business and financial condition.

The most recent analyst rating on (ALDX) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.

Aldeyra Therapeutics Announces Chief Development Officer Resignation

On December 23, 2025, Aldeyra Therapeutics announced that Chief Development Officer Stephen G. Machatha, Ph.D., had voluntarily resigned to pursue other professional opportunities, with his last day to occur on or before March 31, 2026. Under a transition agreement signed the same day, Machatha will remain through the transition period to ensure a smooth handover of responsibilities, continuing to receive his current salary, benefits, and equity vesting, and becoming eligible for up to $176,000 in lump-sum bonus-related payments tied to his 2025 bonus, subject to releases of claims. The company emphasized that his departure was not related to any disagreement over operations, policies, or financial reporting, suggesting that the leadership change is not expected to signal operational or accounting concerns for stakeholders.

The most recent analyst rating on (ALDX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.